Optiver Holding
CADL icon

Optiver Holding’s Candel Therapeutics CADL Stock Holding History

Optiver Holding’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.96K Sell
400
-256
-39% -$1.39K ﹤0.01% 1858
2025
Q4 		$3.71K Hold
656
– – ﹤0.01% 1587
2025
Q3 		$3.35K Buy
+656
New +$3.79K ﹤0.01% 2105

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Optiver Holding's CADL Position: Q1 2026 in Review

Optiver Holding reduced its Candel Therapeutics (CADL) stake by 39% in Q1 2026, selling an estimated $1.39K and leaving 400 shares worth $1.96K. The position accounts for ﹤0.01% of the portfolio, ranked #1858.

Optiver Holding first reported a position in CADL in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.71K in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Optiver Holding held 400 shares of Candel Therapeutics worth $1.96K as of Q1 2026.
  • Optiver Holding sold 256 Candel Therapeutics shares in Q1 2026, an estimated $1.39K.
  • Candel Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #1858 holding.
  • Optiver Holding first reported a position in Candel Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Optiver Holding's Candel Therapeutics position peaked at $3.71K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.